CD274 and colitis: Nielsen et al. [22] reported 11.2–4.9% incidence of mild and severe colitis, respectively, using ipilimumab, vs. 1.2–0.2% incidence using PD-1 inhibitors and 0.3–0.004% incidence using PD-L1 inhibitors.